|
|
Line 3: |
Line 3: |
| <StructureSection load='6x4p' size='340' side='right'caption='[[6x4p]], [[Resolution|resolution]] 1.50Å' scene=''> | | <StructureSection load='6x4p' size='340' side='right'caption='[[6x4p]], [[Resolution|resolution]] 1.50Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6x4p]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6X4P OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6X4P FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6x4p]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6X4P OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6X4P FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UOG:(2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone'>UOG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.5Å</td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PPIA, CYPA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UOG:(2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone'>UOG</scene></td></tr> |
- | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Peptidylprolyl_isomerase Peptidylprolyl isomerase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=5.2.1.8 5.2.1.8] </span></td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6x4p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6x4p OCA], [https://pdbe.org/6x4p PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6x4p RCSB], [https://www.ebi.ac.uk/pdbsum/6x4p PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6x4p ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6x4p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6x4p OCA], [http://pdbe.org/6x4p PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6x4p RCSB], [http://www.ebi.ac.uk/pdbsum/6x4p PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6x4p ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| == Function == | | == Function == |
- | [[http://www.uniprot.org/uniprot/PPIA_HUMAN PPIA_HUMAN]] PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. | + | [https://www.uniprot.org/uniprot/PPIA_HUMAN PPIA_HUMAN] PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 27: |
Line 26: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Peptidylprolyl isomerase]]
| + | [[Category: Appleby TC]] |
- | [[Category: Appleby, T C]] | + | [[Category: Paulsen JL]] |
- | [[Category: Paulsen, J L]] | + | [[Category: Schmitz U]] |
- | [[Category: Schmitz, U]] | + | [[Category: Shivakumar D]] |
- | [[Category: Shivakumar, D]] | + | |
- | [[Category: Cyclophilin some]]
| + | |
- | [[Category: Isomerase-isomerase inhibitor complex]]
| + | |
- | [[Category: Macrocylcic inhibitor]]
| + | |
- | [[Category: Peptidomimetic]]
| + | |
- | [[Category: Prolyl isomerase]]
| + | |
- | [[Category: Sanglifehrin some]]
| + | |
| Structural highlights
Function
PPIA_HUMAN PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
Publication Abstract from PubMed
A tremendous research and development effort was exerted toward combating chronic hepatitis C, ultimately leading to curative oral treatments, all of which are targeting viral proteins. Despite the advantage of numerous targets allowing for broad hepatitis C virus (HCV) genotype coverage, the only host target inhibitors that advanced into clinical development were Cyclosporin A based cyclophilin inhibitors. While cyclosporine-based molecules typically require a fermentation process, Gilead successfully pursued a fully synthetic, oral program based on Sanglifehrin A. The drug discovery process, though greatly helped by facile crystallography, was still hampered by the limitations in the accuracy of predictive computational methods for prioritizing compound ideas. Recent advances in accuracy and speed of free energy perturbation (FEP) methods, however, are attractive for prioritizing and de-risking synthetically challenging molecules and potentially could have had a significant impact on the speed of the development of this program. Here in our simulated prospective study, the binding free energies of 26 macrocyclic cyclophilin inhibitors were blindly predicted using FEP+ to test this hypothesis. The predictions had a low mean unsigned error (MUE) (1.1 kcal/mol) and accurately reproduced many design decisions from the program, suggesting that FEP+ has the potential to drive synthetic chemistry efforts by more accurately ranking compounds with non-intuitive structure-activity relationships (SAR).
Evaluation of Free Energy Calculations for the Prioritization of Macrocycle Synthesis.,Paulsen JL, Yu HS, Sindhikara D, Wang L, Appleby TC, Villasenor AG, Schmitz U, Shivakumar D J Chem Inf Model. 2020 Jun 15. doi: 10.1021/acs.jcim.0c00132. PMID:32539379[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Paulsen JL, Yu HS, Sindhikara D, Wang L, Appleby TC, Villasenor AG, Schmitz U, Shivakumar D. Evaluation of Free Energy Calculations for the Prioritization of Macrocycle Synthesis. J Chem Inf Model. 2020 Jun 15. doi: 10.1021/acs.jcim.0c00132. PMID:32539379 doi:http://dx.doi.org/10.1021/acs.jcim.0c00132
|